AbbVie to Acquire Mitokinin for USD 110m.

MANews-(C)2009-2023

US-based AbbVie (NYSE: ABBV) has exercised its exclusive right and completed the acquisition of US-based discovery-stage biotechnology company Mitokinin, the company said.

Under the terms of the agreement, AbbVie will pay Mitokinin shareholders USD 110 m at closing for the acquisition of Mitokinin.

Mitokinin shareholders remain eligible for potential additional payments of up to USD 545 m upon the achievement of certain development and commercial milestones, plus tiered royalties based on net sales.

Mitokinin is developing a...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT